Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Intellectual Property NGO Action Policy

End Of The 'March-In' Pricing Petitions?

  • News

Executive Summary

KEI vows to continue battle over Bayh-Doyle restrictions after US Commerce Department suggests it may issue regulations to exclude pricing as a basis for requiring companies to license their patents.

Table

View full table

Advertisement

Related Content

Pink Sheet
Building A Wall? The Plan To End “March In” Threat To US Drug Patents
Pink Sheet
Pharma Legislation: From Pricing To Patents
Pink Sheet
Reining In “March In”: NIH Rejects Xtandi Petition
Pink Sheet
Norvir Exclusivity Is Safe; NIH Says "March-In" Test Is Availability, Not Price
Pink Sheet
BARR LABS GRANTED NONEXCLUSIVE AZT LICENSE BY NIH

Topics

Related Companies

Advertisement
Tags:
Intellectual Property NGO Action Policy
UsernamePublicRestriction

Register

PS125176

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By